Chemotherapy Induced Anemia Market: Global Opportunity Analysis and Industry Forecast, 2023-2030 Market

Chemotherapy-induced anemia (CIA) is a consequence of malignant invasion of normal tissues leading to blood loss, bone marrow infiltration with disruption of erythropoiesis, and functional iron deficiency as a consequence of inflammation. CIA is a significant consequence of chemotherapy and may delay or limit therapy as well as contribute to both fatigue and diminished quality of life. Unfortunately, not all clinicians consistently survey, measure, or even document anemia-related symptoms. Furthermore, there are inconsistent thresholds for both definition and severity of anemia. It may also be defined by a reduction from baseline hemoglobin, the use of blood transfusions, or use of recombinant human erythropoietin therapy, others fail to document the toxicity grading system used to define anemia. 

COVID-19 scenario analysis:

Pharmaceutical and biotechnological companies together with governments around the globe are working to combat the COVID-19 outbreak. This is carried out by supporting development of vaccines to schedule for medicines supply chain challenges. Furthermore, there are around 115 vaccine candidates and other 155 molecules that are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have seen huge boost in demand for management of COVID-19. There is an increase in demand for the drug, which has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of the drug. Hence, owing  to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

The major factor affecting the chemotherapy induced anemia market includes surge in occurrence of anemia and cancer among geriatric population. This is anticipated to boost the industry during the forecast period. Furthermore, increase in chronic conditions and rise in number of pipeline products is expected to help the industry gain traction. There has been a rise in innovations of the technology and the government policies are turning out to be favorable such that, it would help the market gain higher revenue in the next few years.

Growth in the number of product developments to boost the market

Growth in number of product developments would help the industry flourish during the forecast period. For instance, in September 2019, FibroGen, Inc. announced first patient dosed in the company’s Phase 2 clinical study of roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of chemotherapy-induced anemia (CIA) in cancer patients receiving chemotherapy.

Roxadustat has been studied in anemia associated with chronic kidney disease in global Phase 3 studies enrolling over 9,000 patients, and is approved for treatment of anemia in CKD patients on dialysis and not on dialysis in China, and in CKD patients on dialysis in Japan, with preparation of the U.S. NDA submission and the European MAA submission underway.

Furthermore, in July 2020, Drug firm Zydus Cadila had received approval from the US health regulator to initiate clinical trials for its drug ‘Desidustat’ in treatment of chemotherapy-induced anemia.

Surge in number of mergers and acquisitions to propel the market

Increase in number of mergers and acquisitions is anticipated to help the industry grow in the coming years. For instance, in October 2019, Dova Pharmaceuticals acquired by Swedish Orphan Biovitrum AB (Sobi) for up to $915m, dependent on the regulatory approval of its lead drug Doptelet in a new indication. Under the terms of the agreement, Sobi offered a consideration of up to $29 per share to Dova stockholders, with an upfront consideration pf $27.50 per share and an additional $1.50 per share upon approval of Doptelet (avatrombopag) for chemotherapy-induced thrombocytopenia (CIT). This amounts to a total potential consideration of up to $915m.

Doptelet is Dova’s first product to receive approval from the FDA as a treatment for low platelet counts (thrombocytopenia) in patients with chronic liver disease, who have to undergo a medical procedure. This was then expanded to patients with chronic immune thrombocytopenia (ITP), who were not benefitted from previous treatment.

Key benefits of the report:

• This study presents the analytical depiction of the global chemotherapy induced anemia industry along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global chemotherapy induced anemia market share.
• The current market is quantitatively analyzed to highlight the global chemotherapy induced anemia market growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the chemotherapy induced anemia market.
• The report provides a detailed global chemotherapy induced anemia market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the chemotherapy induced anemia market research report:

• Which are the leading market players active in the chemotherapy induced anemia market?
• What would be the detailed impact of COVID-19 on the chemotherapy induced anemia market?
• What current trends would influence the chemotherapy induced anemia market in the next few years?
• What are the driving factors, restraints, and opportunities in the chemotherapy induced anemia market?
• What are the projections for the future that would help in taking further strategic steps?

 Chemotherapy Induced Anemia Market: Global Opportunity Analysis and Industry Forecast, 2020–2027 Report Highlights